gemcitabine/nab-paclitaxel

DRUG8 trials

Sponsors

Eli Lilly and Company, Nathan Bahary, MD, Massachusetts General Hospital, Duke University, University Health Network, Toronto

Conditions

Advanced Pancreatic CancerBorderline Resectable Pancreatic CancerBreast CancerColorectal CancerColorectal CarcinomaHead and Neck CancerKRAS-mutant Colorectal Cancer (CRC)KRAS-mutant Non-small Cell Lung Cancer (NSCLC)

Phase 1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

CompletedNCT02009449

Eli Lilly and CompanyBreast Cancer, Colorectal Carcinoma, Melanoma +6

Start: 2013-11-15End: 2023-07-22Updated: 2026-07-09

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

CompletedNCT04666688

PureTechColorectal Cancer, Head and Neck Cancer, Metastatic Cancer +3

Start: 2020-12-15End: 2024-12-12Updated: 2025-02-12

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

RecruitingNCT06922591

Tango Therapeutics, Inc.Lung Cancer, MTAP Deletion, NSCLC +5

Start: 2025-05-31End: 2027-12-01Target: 183Updated: 2026-10-23

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

RecruitingNCT07458347

Kestrel Therapeutics, Inc.KRAS-mutant Colorectal Cancer (CRC), KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) +1

Start: 2026-04-21End: 2029-04-01Target: 545Updated: 2026-10-15

Phase 2

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

TerminatedNCT02241551

Nathan Bahary, MDBorderline Resectable Pancreatic Cancer

Start: 2014-12-31End: 2017-03-03Updated: 2018-07-26

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

TerminatedNCT02243007

Massachusetts General HospitalPancreatic Ductal Carcinoma, Resectable Pancreatic Cancer

Start: 2014-09-30End: 2016-06-30Updated: 2017-05-16

Pancreatic Adenocarcinoma Signature Stratification for Treatment

CompletedNCT04469556

University Health Network, TorontoAdvanced Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma

Start: 2020-10-14End: 2025-03-05Updated: 2026-02-20

Unknown Phase

Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer

CompletedNCT02318095

Duke UniversityResectable Pancreatic Cancers

Start: 2015-02-17End: 2022-11-14Updated: 2023-10-26

Related Papers

Abstract B086: External validation of a multimodal machine learning system to predict outcomes in advanced pancreatic cancer in the PASS-01 trial

Cancer Research2025-09-28

Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.

2024-08-0121 citations

Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.

Journal of Clinical Oncology2024-06-0517 citations

Abstract C063: Keratin 17 as a predictor of chemotherapy response in pancreatic ductal adenocarcinoma

Cancer Research2024-01-16

128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab

Immuno-Oncology Technology2023-12-012 citations

hENT1 as a Predictive Biomarker in PDAC—Response

Clinical Cancer Research2023-08-013 citations

Lyt-200, a Humanized Anti-Galectin-9 Antibody, Exhibits Preclinical Efficacy in Models of Hematological Malignancies

Blood2022-11-156 citations

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Nature Communications2022-08-26116 citations

PASS-01: Pancreatic adenocarcinoma signature stratification for treatment–01.

Journal of Clinical Oncology2022-01-1917 citations

482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

Regular and Young Investigator Award Abstracts2021-11-0110 citations

Abstract IA-08: Clinical advances in pancreas adenocarcinoma

Cancer Research2020-11-131 citations

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

Investigational New Drugs2020-09-1014 citations

Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).

Journal of Clinical Oncology2020-05-202 citations

Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).

Journal of Clinical Oncology2020-05-201 citations

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.

Journal of Clinical Oncology2020-02-191 citations

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

2019-09-25100 citations

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of Oncology2018-10-013 citations

Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Annals of Oncology2018-10-012 citations

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of Oncology2018-10-011 citations

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of Oncology2018-10-01

19 more papers not shown